Pharmasurgics AB – part of the Karolinska Development dermatology and wound healing company “Pergamum” announced that Pharmasurgics has received approval from the Swedish Medical Products Agency to begin a Phase II clinical trial…
Also tagged Clinical Trial, Dermatology, Medical Products Agency, Pergamum, Prevention, Surgical Adhesions, Swedish Medical Products Agency, Wound Healing
Sol-Gel Technologies announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Sol-Gel’s Investigational New Drug Application (IND) for DER45-EV Gel for the topical treatment of rosacea. This IND allows Sol-Gel to initiate Phase II studies with DER45-EV Gel in rosacea patients. DER45-EV Gel is an innovative topical product based [...]
Also tagged Drug Application, Drug Delivery System, Drugs, Efficacy, Fda, Food And Drug, Food And Drug Administration, Food And Drug Administration Fda, Receipt, Rosacea Patients, Sol Gel, Topical Treatment
Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI).
Also tagged Adults, Antibacterial, Bacterial Infections, Clinical Trial, Discovery, Global Problem, Microbial Resistance, Novel Antibiotics, Oral, Pharmaceutical Company, Skin And Skin, Skin Infections, Skin Structure Infections
Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, an Israeli Biopharmaceutical company, announced today the initiation of preparatory work for a Phase III trial with CF101 in Psoriasis. This is based on the successful conclusion of a Phase II dose-response clinical study with CF101 to treat patients with moderate to [...]
Also tagged Aviv Stock, Biopharmaceutical Company, Biotechnology Company, Conclusion, Dose Response, Efficacy, Initiation, Objective, Phase Iii, Preparatory Work, Psoriasis, Tase, Tel Aviv Stock Exchange
Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced that it has received written approval to commence its Phase II clinical trial on its leading topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX6. The double-blind, placebo-controlled study on 80 contact dermatitis patients will take place at the Hadassah Hospital in Israel.
Also tagged Anti Inflammatory Drugs, Biopharmaceutical Company, Biopharmaceuticals, Clinical Trial, Contact Dermatitis, Dermatitis, Double Blind Placebo, Hadassah Hospital, Inflammatory Drug, Institutional Review Board, Israel, Non Steroidal Anti Inflammatory Drugs, Plc
Thallion Pharmaceuticals Inc. (TSX:TLN) announced that it has suspended patient enrollment in its Phase II trial evaluating TLN-232 as a treatment for metastatic melanoma, due to an ongoing dispute with the licensor. A binding arbitration proceeding has been initiated and Thallion will re-evaluate the status of the program based on the outcome of the adjudication.
Also tagged Adjudication, Arbitration Proceeding, Binding Arbitration, Licensor, Melanoma, Metastatic Melanoma, Patient Enrollment, Pharmaceuticals Inc, Tln, Tsx
Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, has achieved yet another goal by completion of patients’ enrollment in its phase II Psoriasis trial. Approximately 70 patients were enrolled to this study, randomized into 4 groups treated with 1, 2 and 4 mg of CF101 and placebo. Patients are taking [...]
Also tagged Aviv Stock, Biotechnology Company, Europe, Groups, Israel, Patient Enrollment, Placebo Patients, Psoriasis, Randomized, Tase, Tel Aviv Stock Exchange
Serentis, a privately owned biopharmaceutical company, announced today that it has commenced patient recruitment in a Phase II clinical trial for atopic dermatitis (AD), a type of eczema. The Phase II, double-blind, vehicle-controlled study will determine the efficacy, safety and tolerability of SRD441 in patients with AD.
Also tagged Atopic Dermatitis, Clinical Trial, Dermatitis, Eczema, Efficacy, Patient Recruitment
Glycotex, Inc. announced the completion of a scheduled interim analysis in a Phase II study evaluating the effect of investigational GLYC-101 gel on complete wound closure and cosmetic outcomes in cosmetic surgery patients undergoing carbon dioxide laser skin resurfacing on the lower eyelid area. The interim analysis was conducted after 26 subjects [...]
Also tagged Carbon Dioxide Laser, Carbon Dioxide Laser Skin Resurfacing, Cosmetic Outcomes, Cosmetic Surgery Patients, Glyc, Glycotex Inc, Interim Analysis, Investigational Compound, Laser Resurfacing, Laser Skin Resurfacing, Wound Closure
Serentis, a privately owned biopharmaceutical company, announced today that it has started a phase II clinical trial in pruritus associated with atopic dermatitis (AD), a type of eczema. Pruritus, more commonly known as itch, is a major symptom of AD. The lack of effective treatments of pruritus has been identified as a [...]
Also tagged Atopic Dermatitis, Clinical Trial, Dermatitis, Eczema, Pruritus, Skin Disease, Unmet Medical Need
